Reuters logo
9 个月前
BRIEF-Alfataliglicerase approved for pediatric indications in Brazil for the treatment of gaucher disease in children four years and older
2016年11月22日 / 下午2点32分 / 9 个月前

BRIEF-Alfataliglicerase approved for pediatric indications in Brazil for the treatment of gaucher disease in children four years and older

Nov 22 (Reuters) - Protalix Biotherapeutics Inc :

* Alfataliglicerase approved for pediatric indications in brazil for the treatment of gaucher disease in children four years and older

* Brazilian National Health Surveillance Agency (bnhsa) has granted regulatory approval for Alfataliglicerase

* Protalix Biotherapeutics-Alfataliglicerase approved as long-term enzyme replacement therapy for children 4 years old & above with type i gaucher disease Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below